<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00981</drugbank-id>
  <drugbank-id>APRD00406</drugbank-id>
  <name>Physostigmine</name>
  <description>A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.</description>
  <cas-number>57-47-6</cas-number>
  <unii>9U1VM840SP</unii>
  <average-mass>275.3461</average-mass>
  <monoisotopic-mass>275.163376931</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Edward J. Glamkowski, Barbara E. Kurys, "4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof." U.S. Patent US5081117, issued September, 1978.</synthesis-reference>
  <indication>For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.</indication>
  <pharmacodynamics>Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia.</pharmacodynamics>
  <mechanism-of-action>Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.</mechanism-of-action>
  <toxicity>Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain.</toxicity>
  <metabolism>Quickly hydrolyzed by cholinesterases</metabolism>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pyrroloindoles. These are compounds containing a pyrroloindole moiety, which is a tricyclic heterocycle which consists of a pyrrole ring fused to an indole. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Indole is a bicyclic  compound consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.</description>
    <direct-parent>Pyrroloindoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Indoles and derivatives</class>
    <subclass>Pyrroloindoles</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Carbamate esters</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Indoles</alternative-parent>
    <alternative-parent>N-alkylpyrrolidines</alternative-parent>
    <alternative-parent>Organic carbonic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyrroles</alternative-parent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbamic acid ester</substituent>
    <substituent>Carbonic acid derivative</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Indole</substituent>
    <substituent>N-alkylpyrrolidine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Pyrrole</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrroloindole</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001541</drugbank-id>
      <name>Physostigmine salicylate</name>
      <unii>2046ZRO9VU</unii>
      <cas-number>57-64-7</cas-number>
      <inchikey>HZOTZTANVBDFOF-PBCQUBLHSA-N</inchikey>
      <average-mass>413.474</average-mass>
      <monoisotopic-mass>413.195070981</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000243</drugbank-id>
      <name>Physostigmine Sulfate</name>
      <unii>G63V2J2N71</unii>
      <cas-number>64-47-1</cas-number>
      <inchikey>YYBNDIVPHIWTPK-KYJQVDHRSA-N</inchikey>
      <average-mass>648.771</average-mass>
      <monoisotopic-mass>648.294133104</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Eserine</synonym>
    <synonym language="english" coder="">Physostigmine</synonym>
    <synonym language="english" coder="">Physostol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Antilirium Inj 1mg/ml</name>
      <labeller>Forest Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00344931</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-07</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-10</started-marketing-on>
      <ended-marketing-on>2018-11-30</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>General Injectables and Vaccines, Inc.a</labeller>
      <ndc-id/>
      <ndc-product-code>52584-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Physostigmine Salicylate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Antilirium</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Physostigmine Salicylate</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
    <mixture>
      <name>Antilirium Inj 1mg/ml</name>
      <ingredients>Physostigmine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amend</name>
      <url/>
    </packager>
    <packager>
      <name>Hope Pharmaceuticals</name>
      <url>http://www.hopepharm.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Nycomed Inc.</name>
      <url>http://www.nycomed.com</url>
    </packager>
    <packager>
      <name>Taylor Pharmaceuticals</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Physostigmine 1 mg/ml ampul</description>
      <cost currency="USD">2.43</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Physostigmine salicyl cryst</description>
      <cost currency="USD">39.48</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Antidotes</category>
      <mesh-id>D000931</mesh-id>
    </category>
    <category>
      <category>Antiglaucoma Preparations and Miotics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>Carbamates</category>
      <mesh-id>D002219</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agents</category>
      <mesh-id>D018678</mesh-id>
    </category>
    <category>
      <category>Cholinesterase Inhibitors</category>
      <mesh-id>D002800</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Indole Alkaloids</category>
      <mesh-id>D026121</mesh-id>
    </category>
    <category>
      <category>Indoles</category>
      <mesh-id>D007211</mesh-id>
    </category>
    <category>
      <category>Miotics</category>
      <mesh-id>D008916</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Parasympathomimetics</category>
      <mesh-id>D010277</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Phenylcarbamates</category>
      <mesh-id>D048448</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>1 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01EB05">
      <level code="S01EB">Parasympathomimetics</level>
      <level code="S01E">ANTIGLAUCOMA PREPARATIONS AND MIOTICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="V03AB19">
      <level code="V03AB">Antidotes</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00981.pdf?1265922743</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Succinylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05875</drugbank-id>
      <name>Sar9, Met (O2)11-Substance P</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04250</drugbank-id>
      <name>Butyrylthiocholine</name>
      <description>Physostigmine may increase the neuromuscular blocking activities of Butyrylthiocholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Tramadol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Trospium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Butabarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Benzatropine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Disopyramide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Talbutal can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Ipratropium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Methadone can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Olanzapine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Metixene can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The therapeutic efficacy of Terfenadine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Buclizine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Clozapine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Doxylamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Procyclidine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Profenamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Promazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The therapeutic efficacy of Imipramine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Amoxapine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Atropine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Nicardipine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Paroxetine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Procaine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Isoflurane can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Clidinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Propiomazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Propantheline can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Primidone can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Biperiden can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Flupentixol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Cocaine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Quinidine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Amantadine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Maprotiline can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Methantheline can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Cycrimine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Tolterodine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Promethazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The therapeutic efficacy of Doxepin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Flavoxate can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The therapeutic efficacy of Desipramine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Chloroprocaine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Escitalopram can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Quetiapine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Diphenidol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Fenoterol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Butobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Tiotropium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Barbituric acid derivative can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Solifenacin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Isopropamide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Gantacurium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Pizotifen can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Dimetindene can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The therapeutic efficacy of Agmatine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Aclidinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Dexetimide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Benactyzine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The therapeutic efficacy of Trimebutine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The therapeutic efficacy of Dosulepin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The therapeutic efficacy of Revefenacin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Oxitropium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Propiverine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Batefenterol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Mebeverine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Tropatepine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Prifinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Piperidolate can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Benzilone can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Difemerine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Mazaticol can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The therapeutic efficacy of Otilonium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Emepronium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Poldine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Bevonium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Rociverine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Bornaprine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Etanautine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Penthienate can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Diphemanil can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Camylofin can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Timepidium can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Physostigmine may increase the bradycardic activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Physostigmine may increase the bradycardic activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Physostigmine may increase the bradycardic activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Physostigmine may increase the bradycardic activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Physostigmine may increase the bradycardic activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Physostigmine may increase the bradycardic activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Physostigmine may increase the bradycardic activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Physostigmine may increase the bradycardic activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Physostigmine may increase the bradycardic activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Physostigmine may increase the bradycardic activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Physostigmine may increase the bradycardic activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Physostigmine may increase the bradycardic activities of Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Physostigmine may increase the bradycardic activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Physostigmine may increase the bradycardic activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Physostigmine may increase the bradycardic activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Physostigmine may increase the bradycardic activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Physostigmine may increase the bradycardic activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Physostigmine may increase the bradycardic activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Physostigmine may increase the bradycardic activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>Physostigmine may increase the bradycardic activities of Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Physostigmine may increase the bradycardic activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Physostigmine may increase the bradycardic activities of Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Physostigmine may increase the bradycardic activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Physostigmine may increase the bradycardic activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Physostigmine may increase the bradycardic activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Physostigmine may increase the bradycardic activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Physostigmine may increase the bradycardic activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Physostigmine may increase the bradycardic activities of Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>Physostigmine may increase the bradycardic activities of Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Physostigmine may increase the bradycardic activities of Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Physostigmine may increase the bradycardic activities of Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Physostigmine may increase the bradycardic activities of Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Physostigmine may increase the bradycardic activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>Physostigmine may increase the bradycardic activities of Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Physostigmine may increase the bradycardic activities of Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Physostigmine may increase the bradycardic activities of Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Physostigmine may increase the bradycardic activities of Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Physostigmine may increase the bradycardic activities of Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Cevimeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00411</drugbank-id>
      <name>Carbamoylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Carbamoylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01019</drugbank-id>
      <name>Bethanechol</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Bethanechol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Varenicline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03128</drugbank-id>
      <name>Acetylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Acetylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04365</drugbank-id>
      <name>Arecoline</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Arecoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05137</drugbank-id>
      <name>Lobeline</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05152</drugbank-id>
      <name>NGX267</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with NGX267.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with GTS-21.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06709</drugbank-id>
      <name>Methacholine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Methacholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07720</drugbank-id>
      <name>Epibatidine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Epibatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15357</drugbank-id>
      <name>Xanomeline</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Xanomeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Physostigmine may decrease the neuromuscular blocking activities of Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of adverse effects can be increased when Physostigmine is combined with Amifampridine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.92e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>physostigmine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>275.3461</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>275.163376931</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C15H21N3O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>PIJVFDBKTWXHHD-HIFRSBDPSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>44.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>78.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>30.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>6.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>7760 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>105.5 C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.58</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>6.12</value>
      <source>MERCK INDEX (1996)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10016</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>27953</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5983</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506998</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06535</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00196</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5763</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>11023</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450957</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000561</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Physostigmine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL94</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/physostigmine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/physostigmine-ophthalmic.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000426</id>
      <name>Acetylcholinesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12237</ref-id>
            <pubmed-id>10368402</pubmed-id>
            <citation>Nguyen PV, Aniksztejn L, Catarsi S, Drapeau P: Maturation of neuromuscular transmission during early development in zebrafish. J Neurophysiol. 1999 Jun;81(6):2852-61.</citation>
          </article>
          <article>
            <ref-id>A12238</ref-id>
            <pubmed-id>10403635</pubmed-id>
            <citation>Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O: Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology. 1999 Jun 15;134(2-3):169-78.</citation>
          </article>
          <article>
            <ref-id>A12239</ref-id>
            <pubmed-id>10741458</pubmed-id>
            <citation>Blasina MF, Faria AC, Gardino PF, Hokoc JN, Almeida OM, de Mello FG, Arruti C, Dajas F: Evidence for a noncholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin. Cell Tissue Res. 2000 Feb;299(2):173-84.</citation>
          </article>
          <article>
            <ref-id>A12240</ref-id>
            <pubmed-id>10873710</pubmed-id>
            <citation>Monnet-Tschudi F, Zurich MG, Schilter B, Costa LG, Honegger P: Maturation-dependent effects of chlorpyrifos and parathion and their oxygen analogs on acetylcholinesterase and neuronal and glial markers in aggregating brain cell cultures. Toxicol Appl Pharmacol. 2000 Jun 15;165(3):175-83.</citation>
          </article>
          <article>
            <ref-id>A12241</ref-id>
            <pubmed-id>11141093</pubmed-id>
            <citation>Bolognesi ML, Andrisano V, Bartolini M, Minarini A, Rosini M, Tumiatti V, Melchiorre C: Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. J Med Chem. 2001 Jan 4;44(1):105-9.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22303" source="Swiss-Prot">
        <name>Acetylcholinesterase</name>
        <general-function>Serine hydrolase activity</general-function>
        <specific-function>Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.</specific-function>
        <gene-name>ACHE</gene-name>
        <locus>7q22</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>6.24</theoretical-pi>
        <molecular-weight>67795.525</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:108</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ACHE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M55040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P22303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACES_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.7</synonym>
          <synonym>AChE</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000849|Acetylcholinesterase
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV
SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN
RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM
NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV
GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL
VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG
VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE
DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY
EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ
YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN
QFDHYSKQDRCSDL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010296|Acetylcholinesterase (ACHE)
ATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC
CTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG
GTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC
TCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA
CCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC
TACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC
CGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA
TCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC
TTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG
AACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC
AATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC
TTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG
GGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC
GGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG
CAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG
GTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG
CCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT
GACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT
GTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC
AACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG
GTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG
GACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC
CCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC
TTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC
GAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG
AAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC
AATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG
TACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC
GCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG
GAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC
CAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
          <pfam>
            <identifier>PF08674</identifier>
            <name>AChE_tetra</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal lamina</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuromuscular junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic cleft</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>collagen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>laminin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process in synaptic cleft</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amyloid precursor protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycerophospholipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle organ development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylcholine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of receptor recycling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0000849</id>
      <name>Neuronal acetylcholine receptor subunit alpha-4</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19891</ref-id>
            <pubmed-id>14645658</pubmed-id>
            <citation>Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P43681" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit alpha-4</name>
        <general-function>Ligand-gated ion channel activity</general-function>
        <specific-function>After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.</specific-function>
        <gene-name>CHRNA4</gene-name>
        <locus>20q13.2-q13.3</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>243-267
275-293
309-330
601-619</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>7.21</theoretical-pi>
        <molecular-weight>69956.47</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1958</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNA4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L35901</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>755648</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43681</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACHA4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NACRA4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001694|Neuronal acetylcholine receptor subunit alpha-4
MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISD
VVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWR
PDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFG
SWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIR
RLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTS
LVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKR
PSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGP
SCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEG
GVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSV
SPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDR
IFLWMFIIVCLLGTVGLFLPPWLAGMI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016224|Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)
ATGGAGCTAGGGGGCCCCGGAGCGCCGCGGCTGCTGCCGCCGCTGCTGCTGCTTCTGGGG
ACCGGCCTCCTGCGCGCCAGCAGCCATGTGGAGACCCGGGCCCACGCCGAGGAGCGGCTC
CTGAAGAAACTCTTCTCCGGTTACAACAAGTGGTCCCGACCCGTGGCCAACATCTCGGAC
GTGGTCCTCGTCCGCTTCGGCCTGTCCATCGCTCAGCTCATTGACGTGGATGAGAAGAAC
CAGATGATGACCACGAACGTATGGGTGAAGCAGGAGTGGCACGACTACAAGCTGCGCTGG
GACCCAGCTGACTATGAGAATGTCACCTCCATCCGCATCCCCTCCGAGCTCATCTGGCGG
CCGGACATCGTCCTCTACAACAATGCTGACGGGGACTTCGCGGTCACCCACCTGACCAAG
GCCCACCTGTTCCATGACGGGCGGGTGCAGTGGACTCCCCCGGCCATTTACAAGAGCTCC
TGCAGCATCGACGTCACCTTCTTCCCCTTCGACCAGCAGAACTGCACCATGAAATTCGGC
TCCTGGACCTACGACAAGGCCAAGATCGACCTGGTGAACATGCACAGCCGCGTGGACCAG
CTGGACTTCTGGGAGAGTGGCGAGTGGGTCATCGTGGATGCCGTGGGCACCTACAACACC
AGGAAGTACGAGTGCTGTGCCGAGATCTACCCGGACATCACCTATGCCTTCGTCATCCGG
CGGCTGCCGCTCTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTGCCTC
ACCGTGCTGGTCTTCTACCTGCCCTCCGAGTGTGGCGAGAAGATCACGCTGTGCATCTCC
GTGCTGCTGTCGCTCACCGTCTTCCTGCTGCTCATCACCGAGATCATCCCGTCCACCTCA
CTGGTCATCCCACTCATCGGCGAGTACCTGCTGTTCACCATGATCTTCGTCACCCTGTCC
ATCGTCATCACGGTCTTCGTGCTCAACGTGCACCACCGCTCGCCACGCACGCACACCATG
CCCACCTGGGTACGCAGGGTCTTCCTGGACATCGTGCCACGCCTGCTCCTCATGAAGCGG
CCGTCCGTGGTCAAGGACAATTGCCGGCGGCTCATCGAGTCCATGCATAAGATGGCCAGT
GCCCCGCGCTTCTGGCCCGAGCCAGAAGGGGAGCCCCCTGCCACGAGCGGCACCCAGAGC
CTGCACCCGCCCTCACCGTCCTTCTGTGTCCCCCTGGATGTGCCGGCTGAGCCTGGGCCT
TCCTGCAAGTCACCCTCCGACCAGCTCCCTCCTCAGCAGCCCCTGGAAGCTGAGAAAGCC
AGCCCCCACCCCTCGCCTGGACCCTGCCGCCCGCCCCACGGCACCCAGGCACCAGGGCTG
GCCAAAGCCAGGTCCCTCAGCGTCCAGCACATGTCCAGCCCTGGCGAAGCGGTGGAAGGC
GGCGTCCGGTGCCGGTCTCGGAGCATCCAGTACTGTGTTCCCCGAGACGATGCCGCCCCC
GAGGCAGATGGCCAGGCTGCCGGCGCCCTGGCCTCTCGCAACACCCACTCGGCTGAGCTC
CCACCCCCAGACCAGCCCTCTCCGTGCAAATGCACATGCAAGAAGGAGCCCTCTTCGGTG
TCCCCGAGCGCCACGGTCAAGACCCGCAGCACCAAAGCGCCGCCCCCGCACCTGCCCCTG
TCGCCGGCCCTGACCCGGGCGGTGGAGGGCGTCCAGTACATTGCAGACCACCTGAAGGCC
GAAGACACAGACTTCTCGGTGAAGGAGGACTGGAAGTACGTGGCCATGGTCATCGACCGC
ATCTTCCTCTGGATGTTCATCATCGTCTGCCTGCTGGGGACGGTGGGCCTCTTCCTGCCG
CCCTGGCTGGCTGGCATGATCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exploration behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibitory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory gaseous exchange</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000850</id>
      <name>Neuronal acetylcholine receptor subunit beta-2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19891</ref-id>
            <pubmed-id>14645658</pubmed-id>
            <citation>Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P17787" source="Swiss-Prot">
        <name>Neuronal acetylcholine receptor subunit beta-2</name>
        <general-function>Ligand-gated ion channel activity</general-function>
        <specific-function>After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.</specific-function>
        <gene-name>CHRNB2</gene-name>
        <locus>1q21.3</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>234-258
266-284
300-321
459-478</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>6.77</theoretical-pi>
        <molecular-weight>57018.575</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1962</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRNB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X53179</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32017</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>472</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P17787</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACHB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neuronal acetylcholine receptor subunit beta-2 precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010600|Neuronal acetylcholine receptor subunit beta-2
MARRCGPVALLLGFGLLRLCSGVWGTDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQL
MVSLAQLISVHEREQIMTTNVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLY
NNADGMYEVSFYSNAVVSYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDR
TEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRKPLFYTIN
LIIPCVLITSLAILVFYLPSDCGEKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVGKY
LMFTMVLVTFSIVTSVCVLNVHHRSPTTHTMAPWVKVVFLEKLPALLFMQQPRHHCARQR
LRLRRRQREREGAGALFFREAPGADSCTCFVNRASVQGLAGAFGAEPAPVAGPGRSGEPC
GCGLREAVDGVRFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTIGMFLQ
PLFQNYTTTTFLHSDHSAPSSK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010601|Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)
ATGGCCCGGCGCTGCGGCCCCGTGGCGCTGCTCCTTGGCTTCGGCCTCCTCCGGCTGTGC
TCAGGGGTGTGGGGTACGGATACAGAGGAGCGGCTGGTGGAGCATCTCCTGGATCCTTCC
CGCTACAACAAGCTTATCCGCCCAGCCACCAATGGCTCTGAGCTGGTGACAGTACAGCTT
ATGGTGTCACTGGCCCAGCTCATCAGTGTGCATGAGCGGGAGCAGATCATGACCACCAAT
GTCTGGCTGACCCAGGAGTGGGAAGATTATCGCCTCACCTGGAAGCCTGAAGAGTTTGAC
AACATGAAGAAAGTTCGGCTCCCTTCCAAACACATCTGGCTCCCAGATGTGGTCCTGTAC
AACAATGCTGACGGCATGTACGAGGTGTCCTTCTATTCCAATGCCGTGGTCTCCTATGAT
GGCAGCATCTTCTGGCTGCCGCCTGCCATCTACAAGAGCGCATGCAAGATTGAAGTAAAG
CACTTCCCATTTGACCAGCAGAACTGCACCATGAAGTTCCGTTCGTGGACCTACGACCGC
ACAGAGATCGACTTGGTGCTGAAGAGTGAGGTGGCCAGCCTGGACGACTTCACACCTAGT
GGTGAGTGGGACATCGTGGCGCTGCCGGGCCGGCGCAACGAGAACCCCGACGACTCTACG
TACGTGGACATCACGTATGACTTCATCATTCGCCGCAAGCCGCTCTTCTACACCATCAAC
CTCATCATCCCCTGTGTGCTCATCACCTCGCTAGCCATCCTTGTCTTCTACCTGCCATCC
GACTGTGGCGAGAAGATGACGTTGTGCATCTCAGTGCTGCTGGCGCTCACGGTCTTCCTG
CTGCTCATCTCCAAGATCGTGCCTCCCACCTCCCTCGACGTGCCGCTCGTCGGCAAGTAC
CTCATGTTCACCATGGTGCTTGTCACCTTCTCCATCGTCACCAGCGTGTGCGTGCTCAAC
GTGCACCACCGCTCGCCCACCACGCACACCATGGCGCCCTGGGTGAAGGTCGTCTTCCTG
GAGAAGCTGCCCGCGCTGCTCTTCATGCAGCAGCCACGCCATCATTGCGCCCGTCAGCGC
CTGCGCCTGCGGCGACGCCAGCGTGAGCGCGAGGGCGCTGGAGCCCTCTTCTTCCGCGAA
GCCCCAGGGGCCGACTCCTGCACGTGCTTCGTCAACCGCGCGTCGGTGCAGGGGTTGGCC
GGGGCCTTCGGGGCTGAGCCTGCACCAGTGGCGGGCCCCGGGCGCTCAGGGGAGCCGTGT
GGCTGTGGCCTCCGGGAGGCGGTGGACGGCGTGCGCTTCATCGCAGACCACATGCGGAGC
GAGGACGATGACCAGAGCGTGAGTGAGGACTGGAAGTACGTCGCCATGGTGATCGACCGC
CTCTTCCTCTGGATCTTTGTCTTTGTCTGTGTCTTTGGCACCATCGGCATGTTCCTGCAG
CCTCTCTTCCAGAACTACACCACCACCACCTTCCTCCACTCAGACCACTCAGCCCCCAGC
TCCAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acetylcholine-gated channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>central nervous system projection neuron axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>conditioned taste aversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lateral geniculate nucleus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>optic nerve morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of B cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian sleep/wake cycle, non-REM sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian sleep/wake cycle, REM sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dendrite morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission involved in micturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vestibulocochlear nerve development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>